丹麦制药巨头诺和诺德(Novo Nordisk,NYSE:NVO)近日公布了2026年第二季度及上半年部分关键财务指标。财报显示,今年上半年,诺和诺德实现总营收1753.11亿丹麦克朗(约273.8亿美元),按固定汇率计算同比增长13%;实现归属于母公司股东的净利润695.46亿丹麦克朗(约108.6亿美元),同比增长25.22%。 第二季度调整后销售额达784.88亿丹麦克朗(约120.9...
Source Link丹麦制药巨头诺和诺德(Novo Nordisk,NYSE:NVO)近日公布了2026年第二季度及上半年部分关键财务指标。财报显示,今年上半年,诺和诺德实现总营收1753.11亿丹麦克朗(约273.8亿美元),按固定汇率计算同比增长13%;实现归属于母公司股东的净利润695.46亿丹麦克朗(约108.6亿美元),同比增长25.22%。 第二季度调整后销售额达784.88亿丹麦克朗(约120.9...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.